Survey reflects shift towards more varied data sources

7 November 2017

As many as 97% of life science companies expect to use more clinical data from a wider variety of sources over the next three years to make faster, more accurate decisions during trials, according to new research from Tufts Center for the Study of Drug Development.

This is one of the findings of the 2017 eClinical Landscape Study, one of the largest, most in-depth surveys of clinical data management professionals, which found that companies use an average of four data sources in clinical trials today.

In three years, the number of data sources utilized is projected to increase to six, with 70% of companies planning to use a new data source that they are not leveraging today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK